Last reviewed · How we verify

loperamide-simethicone — Competitive Intelligence Brief

loperamide-simethicone (loperamide-simethicone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiarrheal combination agent. Area: Gastroenterology.

marketed Antidiarrheal combination agent Mu-opioid receptor (loperamide component); antifoaming agent (simethicone component) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

loperamide-simethicone (loperamide-simethicone) — Johnson & Johnson Consumer and Personal Products Worldwide. Loperamide-simethicone combines an antimotility agent that slows intestinal movement with an anti-gas agent that reduces bloating and flatulence.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
loperamide-simethicone TARGET loperamide-simethicone Johnson & Johnson Consumer and Personal Products Worldwide marketed Antidiarrheal combination agent Mu-opioid receptor (loperamide component); antifoaming agent (simethicone component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiarrheal combination agent class)

  1. Johnson & Johnson Consumer and Personal Products Worldwide · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). loperamide-simethicone — Competitive Intelligence Brief. https://druglandscape.com/ci/loperamide-simethicone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: